Merck (MRK) Inventory Average (2009 - 2026)
Merck (MRK) reported Inventory Average of $6.6 billion for Q1 2026, up 6.76% year-over-year from $6.2 billion in Q1 2025, and little changed on a QoQ basis from $6.6 billion in Q4 2025.
Merck (MRK) has 18 years of Inventory Average data on file, last reported at $6.6 billion in Q1 2026.
- Quarterly Inventory Average rose 6.76% year-over-year to $6.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 billion (up 6.76% YoY) and the FY2025 annual result came in at $6.4 billion, up 2.41% from the prior year.
- Inventory Average held at $6.6 billion in Q1 2026 per MRK's latest filing, from $6.6 billion in the prior quarter.
- Across five years, Inventory Average topped out at $6.6 billion in Q1 2026 and bottomed at $5.6 billion in Q3 2022.
- The 5-year median for Inventory Average is $6.2 billion (2024), against an average of $6.2 billion.
- The widest annual swing landed in 2022, when Inventory Average dropped 4.97%; it then climbed 10.06% in 2024.
- Tracing MRK's Inventory Average over 5 years: stood at $5.8 billion in 2022, then rose by 8.36% to $6.2 billion in 2023, then dropped by 1.09% to $6.2 billion in 2024, then grew by 6.06% to $6.6 billion in 2025, then gained by 0.27% to $6.6 billion in 2026.
- Per Business Quant, the three latest MRK Inventory Average figures stand at $6.6 billion (Q1 2026), $6.6 billion (Q4 2025), and $6.5 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 2.74 Bn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 14.14 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 14.39 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 5.00 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 6.57 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 6.21 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.84 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 10.66 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.72 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 7.58 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.57 Bn |
| Dec 31, 2025 | 6.55 Bn |
| Sep 30, 2025 | 6.52 Bn |
| Jun 30, 2025 | 6.40 Bn |
| Mar 31, 2025 | 6.15 Bn |
| Dec 31, 2024 | 6.18 Bn |
| Sep 30, 2024 | 6.36 Bn |
| Jun 30, 2024 | 6.49 Bn |
| Mar 31, 2024 | 6.43 Bn |
| Dec 31, 2023 | 6.24 Bn |
| Sep 30, 2023 | 6.03 Bn |
| Jun 30, 2023 | 5.90 Bn |
| Mar 31, 2023 | 5.89 Bn |
| Dec 31, 2022 | 5.76 Bn |
| Sep 30, 2022 | 5.57 Bn |
| Jun 30, 2022 | 5.65 Bn |
| Mar 31, 2022 | 5.86 Bn |
| Dec 31, 2021 | 5.78 Bn |
| Sep 30, 2021 | 5.55 Bn |
| Jun 30, 2021 | 5.95 Bn |
| Mar 31, 2021 | 5.98 Bn |
| Dec 31, 2020 | 5.84 Bn |
| Sep 30, 2020 | 6.09 Bn |
| Jun 30, 2020 | 5.95 Bn |
| Mar 31, 2020 | 5.91 Bn |
| Dec 31, 2019 | 5.92 Bn |
| Sep 30, 2019 | 5.85 Bn |
| Jun 30, 2019 | 5.78 Bn |
| Mar 31, 2019 | 5.58 Bn |
| Dec 31, 2018 | 5.43 Bn |
| Sep 30, 2018 | 5.30 Bn |
| Jun 30, 2018 | 5.28 Bn |
| Mar 31, 2018 | 5.24 Bn |
| Dec 31, 2017 | 5.18 Bn |
| Sep 30, 2017 | 5.34 Bn |
| Jun 30, 2017 | 5.28 Bn |
| Mar 31, 2017 | 5.01 Bn |
| Dec 31, 2016 | 5.06 Bn |
| Sep 30, 2016 | 5.25 Bn |
| Jun 30, 2016 | 5.18 Bn |
| Mar 31, 2016 | 4.90 Bn |
| Dec 31, 2015 | 4.91 Bn |
| Sep 30, 2015 | 5.21 Bn |
| Jun 30, 2015 | 5.42 Bn |
| Mar 31, 2015 | 5.56 Bn |
| Dec 31, 2014 | 5.70 Bn |
| Sep 30, 2014 | 5.98 Bn |
| Jun 30, 2014 | 6.26 Bn |
| Mar 31, 2014 | 6.30 Bn |
| Dec 31, 2013 | 6.48 Bn |
| Sep 30, 2013 | 6.75 Bn |
| Jun 30, 2012 | 6.29 Bn |
| Mar 31, 2012 | 6.30 Bn |
| Dec 31, 2011 | 6.25 Bn |
| Sep 30, 2011 | 6.23 Bn |
| Jun 30, 2011 | 6.14 Bn |
| Mar 31, 2011 | 5.96 Bn |
| Dec 31, 2010 | 6.07 Bn |
| Sep 30, 2010 | 6.25 Bn |
| Jun 30, 2010 | 6.53 Bn |
| Mar 31, 2010 | 7.44 Bn |
| Dec 31, 2009 | 5.75 Bn |
| Sep 30, 2009 | 3.47 Bn |